Neuroendocrine Tumors

Kulke, Matthew H.; Benson, Al B.; Bergsland, Emily K.; Berlin, Jordan; Blaszkowsky, Lawrence S.; Choti, Michael A.; Clark, Orlo H.; Doherty, Gerard M.; Eason, James; Emerson, Lyska L.; Engstrom, Paul F.; Goldner, Whitney; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Moley, Jeffrey F.; Pillarisetty, Venu G.; Saltz, Leonard; Schteingart, D.E.; Shah, Manisha H.; Shibata, Stephen; Strosberg, Jonathan R.; Vauthey, Jean Nicolas; White, Rebekah R.; Yao, James C.

doi:10.6004/jnccn.2012.0075

Cited by 170 publications

(134 citation statements)

References 132 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…For these patients, standard dosing may not be sufficient to obtain symptom control; therefore, an above-standard dose of SSA may be considered as an attempt to control CS symptoms associated with NET. Additional recommendations (e.g.,National Comprehensive Cancer Network) and consensus reports have recommended considering an increase of dosage or dose frequency of octreotide LAR for refractory CS symptoms [18][19][20].…”

Section: (85)mentioning

confidence: 99%

Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background. Octreotide LAR is used in patients for control of carcinoid syndrome (CS) and other symptoms of hormone hypersecretion. The aim of this study was to examine reasons for octreotide LAR dose escalation and observe CS symptom improvement in patients with neuroendocrine tumors (NETs) who underwent octreotide LAR dose escalation at three cancer referral centers. Methods. Medical records for patients with diagnosis of carcinoid or pancreatic NET who had received one dose or more of octreotide LAR above 30 mg every 4 weeks from 2000 to 2012 were reviewed. Reasons for dose escalation and symptomatic outcomes were abstracted for each patient 3 months prior to and up to 12 months following the dose escalation. Results. Of the evaluated 239 NET patients, 53% were male, mean age at first dose escalation was 60 years (standard deviation [SD]: 11 years), and mean time from octreotide LAR

show abstract

Section: (85)mentioning

confidence: 99%

Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Incluyen una amplia familia de tumores, de los cuales los más frecuentes son los carcinoides y los tumores neuroendocrinos del páncreas (TNEP) 2 . Los TNEP representan aproximadamente el 2% de los tumores gastrointestinales y el 1-2% de los tumores pancreáticos 3 .…”

Section: Introductionunclassified

Tumores neuroendocrinos del páncreas: Resultados quirúrgicos y sobrevida alejada

et al. 2013

Rev Chil Cir

View full text Add to dashboard Cite

“…According to the National Comprehensive Cancer Network guidelines and American Joint Committee on Cancer staging of gastrointestinal NETs (14), T1 tumors that are limited to the lamina propria or submucosa and present a diameter of <1 cm (the diameter of colorectal and appendix ≤2 cm), are considered appropriate for endoscopic resection (15,16). However, previous studies have reported that patients with such tumors have experienced lymphatic-vascular involvement and exhibit the risk of recurrence and metastasis following endoscopic resection (13).…”

Section: Introductionmentioning

confidence: 99%

Early diagnosis and treatment of gastrointestinal neuroendocrine tumors

Shen

Zhao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present retrospective analysis on the macroscopic appearance and pathological characteristics of gastrointestinal neuroendocrine tumors (NETs) was to investigate methods for their early diagnosis and treatment. A total of 78 patients were divided into submucosal NET and deeper invasion NET groups, according to the depth of tumor invasion exhibited by the patients. The clinicopathological characteristics and survival time of the NET patients were analyzed and compared. The pathological characteristics of the submucosal NETs group were investigated according to the diameter of the tumor (≤5.0 mm, 5.1-10.0 mm or >10.0 mm). The depth of invasion at diagnosis was observed to significantly correlate with histopathological classification, diameter of the tumor, macroscopic appearance, growth pattern, lymphatic-vascular involvement, lymph node (LN) metastasis and distant metastasis. In the submucosal NETs group, high-grade tumors with lymphatic or venule invasion and distant metastasis were associated with an increased risk of nodal metastases. In patients with minute tumors (≤5.0 mm), no lymphatic-vascular involvement, LN or distant metastasis was observed. By contrast, patients with tumors measuring 5.1-10.0 mm in diameter exhibited high lymphatic-vascular involvement and LN metastasis rates (46.2 and 30.8%, respectively). Survival time was significantly longer in patients with submucosal NETs compared with deeper invasion NETs and in patients with NET G1 and NET G2 compared with NEC. The results of the present study indicate that gastrointestinal submucosal NETs are closely associated with a slightly elevated macroscopic type, low-grade tumors and a small diameter. These features may contribute to early diagnosis of gastrointestinal NETs. Therefore, a tumor diameter of <5.0 mm, with slightly elevated macroscopic appearance may indicate an absolute requirement for endoscopic resection, while tumors measuring 5.1-10.0 mm in diameter must be considered carefully.

show abstract

Neuroendocrine Tumors

Cited by 170 publications

References 132 publications

Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

Tumores neuroendocrinos del páncreas: Resultados quirúrgicos y sobrevida alejada

Early diagnosis and treatment of gastrointestinal neuroendocrine tumors

Contact Info

Product

Resources

About